Key facts
- MedScout’s last known valuation is $83.0M (Feb 2026).
- It has raised $31.6M; the latest was Later Stage VC ($10.0M) in Feb 2026.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Capital Factory, Stage 2 Capital, LiveOak Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for MedScout
- ·The full record, as it builds
Funding rounds
No funding rounds for MedScout are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MedScout
Developer of sales enablement software designed to run a data-driven sales cycle for life sciences companies. The company's platform provides information on affiliation, patient demographics, multiple years of procedure volume, referral, and payment data, as well as simplifying market analysis, strategy development, and sales execution, enabling its clients to optimize operational productivity and growth effectively.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2020
- Employees
- 49
- Website
- medscout.io/
- Ownership
- Privately Held (backing)
MedScout doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MedScout shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MedScout in its N-PORT filings yet. We sweep new filings monthly.